The annual Director's Awards recognized four individuals and teams including awards for leadership in quantum simulation development and application on high-performance computing platforms, and revolutionary advancements in the area of microbial
David Kropaczek, director of the Consortium for Advanced Simulation of Light Water Reactors, or CASL, at the Department of Energy’s Oak Ridge National Laboratory, has been named a fellow of the American Nuclear Society.
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.
ORNL has added 10 virtual tours to its campus map, each with multiple views to show floor plans, rotating dollhouse views and 360-degree navigation. As a user travels through a map, pop-out informational windows deliver facts, videos, graphics and links to other related content.
To better understand how the novel coronavirus behaves and how it can be stopped, scientists have completed a three-dimensional map that reveals the location of every atom in an enzyme molecule critical to SARS-CoV-2 reproduction.
Four research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received 2020 R&D 100 Awards.
Experts at the Department of Energy’s Oak Ridge National Laboratory are now offering short-term technical and scientific assistance to entities working to combat the coronavirus through the COVID-19 Technical Assistance Program, an initiative of DOE’s Office of Technology Transitions.
A team led by Dan Jacobson of Oak Ridge National Laboratory used the Summit supercomputer at ORNL to analyze genes from cells in the lung fluid of nine COVID-19 patients compared with 40 control patients.
A team of researchers has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease — the enzyme that enables the virus to reproduce.
Oak Ridge National Laboratory has launched a program designed to accelerate deployment of innovations that may help fight the COVID-19 pandemic. The COVID-19 Rapid Access Licensing Program will allow companies to license these select technologies at no cost for one year.